AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03812510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101
Description: hydrogen peroxide topical solution 45%
Study NCT00764725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional DMARD combination
Description: MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
Study NCT00764725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MTX plus anti-TNF
Description: MTX + infliximab; can be changed to MTX + etanercept within protocol
Study NCT01636557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
Study NCT01636557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study NCT01636557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study NCT01636557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study NCT01636557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study NCT01636557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study NCT02635204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD06 Cream
Description: Twice daily topical application for 14 days.
Study NCT02635204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Twice daily topical application for 14 days.
Study NCT04552470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 matching placebo tablets taken twice a day (BID)
Study NCT04552470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
Study NCT03399383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
Study NCT01021111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Training with Feedback
Description: The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
Study NCT02304003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Physiotherapy Regimen
Description: Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
Study NCT02304003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard follow up in primary care.
Study NCT00759603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
Study NCT00759603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
Study NCT01145560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9773
Description: A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
Study NCT01145560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03431220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device
Description: NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
Study NCT00693706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine GSK 138842A
Description: IM injection on Day 0
Study NCT00693706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: IM injection on Day 0
Study NCT00816803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplant
Study NCT00816803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical therapy
Study NCT00816803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Study NCT03603743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training in heart failure with HIIT
Description: to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
Study NCT03603743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training in heart failure with HIIT
Description: to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
Study NCT03120143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small-sided ball game training with high protein intake
Description: In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
Study NCT03120143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small-sided ball game training with low protein intake
Description: n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
Study NCT00519077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
Study NCT05492279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sunflower oil
Description: natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
Study NCT04907838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin clamp
Description: Continous infusion insulin + glucose
Study NCT04907838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Continuous infusion of Insulin + glucose + BQ123
Study NCT04907838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123 + BQ788
Description: Continous infusion of insulin + glucose + BQ123 + BQ788
Study NCT03558724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
Study NCT03276143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg enoxaparin administered as subcutaneous injection once daily
Study NCT03276143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 2.5 mg apixaban administered as tablet orally twice daily
Study NCT03276143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single dose of BAY1213790 administered as intravenous infusion
Study NCT02811107 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
Study NCT00704353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: 15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
Study NCT00704353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC)
Description: Per product label
Study NCT01454284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Study NCT01454284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT01454284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Study NCT01454284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Study NCT01814085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
Study NCT00861406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-Alfa 2b (PEG Intron)
Description: Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks.
Study NCT00861406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP-100 Peptide Vaccine
Description: Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
Study NCT01193335 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
Study NCT01018407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discrete Trial Training
Description: UCLA model, developed by Lovaas and colleagues (Smith, Groen \& Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program.
Study NCT01018407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Developmental Approach
Description: Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities.
Study NCT02126488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill slip perturbation
Description: Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
Study NCT02126488 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: treadmill training placebo
Description: An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
Study NCT02126488 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: observation training
Description: An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
Study NCT03192904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy Instruments
Description: Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
Study NCT03192904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stapling Device
Description: Stapling Device, including linear stapler and curved stapler.
Study NCT01938287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Study NCT02814721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonic Window ultrasound device
Study NCT04846114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant surgery
Study NCT04846114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant surgery
Study NCT03588689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca block
Description: Regional nerve block performed under ultrasound guidance. A catheter will be left in place to allow ongoing infusion of local anesthetic.
Study NCT03588689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine local anesthetic will be used for the fascia iliaca block
Study NCT00158366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training
Description: The behavioral training will teach participants ways to control their diet and increase their physical activity.
Study NCT00158366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social skills training
Description: The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
Study NCT00158366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training booster sessions
Description: During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
Study NCT00384579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Description: Botulinum Toxin B
Study NCT01149473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium/Hydrochlorothiazide
Description: 100/25 mg Tablets
Study NCT01149473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan potassium/Hydrochlorothiazide
Description: 100/25 mg Tablets
Study NCT01963806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone-supplemented iCBT
Description: The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support.
Study NCT04457284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +
Study NCT04457284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +
Study NCT04457284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg Q4W IV infusion Cycle 1 +
Study NCT00384579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03689595 — intervention group
Intervention type: OTHER
Intervention: Sample of Blood
Description: Collection of blood sample from participants
Study NCT03347435 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435
Description: The CYP2C19\*2 (10q24.1-q24.3; rs4244285), CYP2C19\*17 (10q24.1-q24.3; rs12248560) and ABCB1 3435 (7q21.1; rs1045642) genetic variants will be genotyped using an ST Q3 system. The conventional genotyping methods so far used for diagnostic purposes will not be used in this study because appropriate labs may not be readily available and the processing time is prohibitive. Q3 is a compact platform enabling the classical laboratory analysis of DNA by means of real-time PCR. The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. Antiplatelet therapy will be choose on the basis of clinical and genetic algorithm.
Study NCT03347435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical algorithm
Description: Antiplatelet therapy will be choose on the basis of clinical algorithm alone
Study NCT03663179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (\~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
Study NCT03663179 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation (Sham TMS)
Description: A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).